Digital Health Literacy and Oocyte Cryopreservation Among Women With Gynecological Cancer (NCT07701252) | Clinical Trial Compass
CompletedNot Applicable
Digital Health Literacy and Oocyte Cryopreservation Among Women With Gynecological Cancer
Egypt158 participantsStarted 2025-09-01
Plain-language summary
This study evaluated a digital health literacy education intervention related to oocyte cryopreservation among newly diagnosed women with gynecological cancer. A quasi-experimental single-group pre-post design was used at the Outpatient Clinics of the Oncology Center, Mansoura University Hospital, Egypt. A purposive sample of 158 women participated. Outcomes were measured before and after the intervention and included knowledge about oocyte cryopreservation, attitudes toward oocyte cryopreservation, and decisional conflict. The intervention used videos, images, WhatsApp, Zoom, Microsoft Teams, PowerPoint slides, short text messages, simple Arabic-language educational materials, and follow-up through phone or social media when needed. Outcomes were reassessed at the end of week 4.
Who can participate
Age range
18 Years – 45 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Newly diagnosed women with gynecological cancers who had not received any treatment.
* Women of reproductive age, 18-45 years.
* Women with gynecological cancers who had not received cryopreservation instructions before.
* Women who had a smartphone, internet connection, could use social media, and had access to the internet through their phone.
Exclusion Criteria:
* Women with gynecological cancer who had received cancer treatment, including chemotherapy, radiotherapy, or hormonal therapy.
* Women diagnosed with learning difficulties, such as dementia or vision impairment.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Knowledge Regarding Oocyte Cryopreservation
Timeframe: Pre-intervention and end of week 4
2
Change in Attitude Toward Oocyte Cryopreservation
Timeframe: Pre-intervention and end of week 4
3
Change in Decisional Conflict Regarding Oocyte Cryopreservation